More articles from Volume 44, Issue 1, 2015
HLORINIŠUĆA AKTIVNOST SERUMSKE MIJELOPEROKSIDAZE U AKUTNOM ISHEMIČNOM MOŽDANOM UDARU
KVANTITATIVNA ANALIZA MAKROFAGA U GINGIVITISU I PARODONTOPATIJI
Is hypertension, in children who are on chronic hemodialysis therapy, crucial for the development of cardiac hypertrophy?
LEČENJE INFERTILNIH I SUBFERTILNIH MUŠKARACA SA VARIKOKELOM MINIMALNO INVAZIVNIM HIRURŠKIM METODOM
HISTOLOŠKO-CITOLOŠKA KORELACIJA NALAZA I POUZDANOST PAPANICOLAU TESTA U OTKRIVANJU PREMALIGNIH I MALIGNIH PROMENA NA GRLIĆU MATERICE
HISTOLOŠKO-CITOLOŠKA KORELACIJA NALAZA I POUZDANOST PAPANICOLAU TESTA U OTKRIVANJU PREMALIGNIH I MALIGNIH PROMENA NA GRLIĆU MATERICE
,
L. Vitkovic
,
M. Mijovic
,
D. Vukicevic
,
B. Djerkovic
,
N. Mitic
,
A. Ilic
,
G. Trajkovic
S. Jakovljevic
Abstract
Keywords
References
1.
Vitković L. Značaj molekularnih markera u histološkoj i citološkoj analizi epitela grlića materice. 2011;
2.
Žuža-Jurica S, Dabo J, Utješinović-Gudelj V, Oluić-Kabalin G, Mozetič V. Humani papiloma virus: prevencija, cijepljenje, liječenje. 2009;(1):49–55.
3.
Parkin D, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine. 2006;(3):11–25.
4.
Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci. 2006;525–41.
5.
Villiers D, Fauquet EM, Brocer C, Bernard T, Zur Hausen HU, H. Classification of papillomaviruses. Virology. 2004;17–27.
6.
Subramanya D, Grivas P. HPV and cervical cancer: up¬dates on an established relationship. Postgrad Med. 2008;7–13.
7.
Vitković L, Mitić B, Piperski V, Trajković G, Anđeliković Z, Vukićević D, et al. Ekspresija proteina p16INK4a u normalnom i displastično promenjenom epitelu grlića materice. Naučni časopis Medicinskog fakulteta i Društva lekara Kosova i Metohije SLD-Praxis medica. 2011;(3–4):13–7.
8.
Gharizadeh B, Calantari M, Garsia C, Johanson B, Nyren P. Typing of human papillomavirus by pyrosequencing. Lab Invest. 2001;673–9.
9.
Lacey C. Assessment of exposure to sexually transmitted agents other than human papillomavirus. IARC Scientific Publications. 1992;(119):93–105.
10.
Halfon P, Trepo E, Antoniotti G, Bernot C, Cart-Lamy P, Khiri H. Prospective Evaluation of the Hybrid Capture 2 and AMPLICOR Human Papillomavirus (HPV) Test for detection of 13 High-Risk HPV Genotypes in Atypical Aquamous cells of Uncertain Significance. J Clin Microbiol. 2007;(2):313–6.
11.
Reddout N, Christensen T, Bunell A, Jensen D, Jonson D, O´malley S. High risk HPV types 18 and 16 are potent modulators of oral squamous cell carcinoma phenotypes in vitro. Infect Agent Cancer. 2007;21–33.
12.
Uuskũla A, Kals M, Kosenkanius L, Mcnutt L, Hovitz D, J. Population based type-specific, prevalence of high-risk human papillomavirus infection in Estonia. Infectius Diseases. 2010;63.
13.
Ho G, Burk R, Klein S, Kadish A, Chang C, Palan P. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995;(18):1365–71.
14.
Franco E, Franco D, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ. 2001;(7):1017–25.
15.
Santos C, Munoz N, Klug S, Almonte M, Guerrero I, Alvarez M. HPV types and cofactors causing cervical cancer in Peru. Br J Cancer. 2001;966–71.
16.
Castellsague X, Munoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis -Role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003;20–8.
17.
Wang S, Hildesheim A. Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr. 2003;35–40.
18.
Iarc. IARC Monographs on the evaluation of Carcinogenic Risks to Humans. 2007;
19.
Solomon D. The 1988 Bethesda system for reporting cervical/vaginal citologic diagnoses. Acta Cytol. 1989;567–74.
20.
Popović-Lazić J. 2006;23–6.
21.
Zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nature. 2002;342–50.
22.
Von K, Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. European Journal of Cancer. 2002;2229–42.
23.
Iarc. IARC Handbooks of Cancer Research Prevention. Cervix Cancer Screening. 2005;
24.
Papanicolaou G, Traut H. Tha diagnostic value of vaginal smears in carcinoma of the uterus. Arch Pathol Lab med. 1941;211–24.
25.
Nanda K, Mccrory D, Myers E, Bastian L, Hasselblad V, Hickey J. Accuracy of the Papanicolaou Test in Screening for and Fallow-up of Cervical Cytologic Abnormalities: A Systematic Review. Ann Intern Med. 2000;810–9.
26.
Trajović P, Z. Citološka slika cervikalnih intraepitelnih neoplazija. U: Stanimirović B (urednik) Dijagnostika i lečenje oboljenja cerviksa, vagine i vulve. Kolposkopski atlas. Elit-Medica. 2006;9–12.
27.
Pavlović S. Citologija ženskih genitalija. 1980;
28.
Liaw K, Glass A, Manos M, Greer C, Scott D, Sherman M. Detection of human papillomavirus DNA in cytological normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst. 1999;954–60.
29.
Panjković M, Ivković-Kapicl T. Etiologyand pathogenesis of precancerous lesions and invasive cervical carcinoma. Med Pregl. 2008;(7–8):364–8.
30.
Solomon D, Davey D, Kurman R. JAMA. 2002;2114–9.
31.
The 1988 Bethesda system for reporting cervical/vaginal cytologic diagnosis. JAMA. 1989;931–4.
32.
Gingrich P. Management and follow-up of abnormal Papanicolaou tests. J Am Med Wom Associat. 2004;54–60.
33.
Yuce K. 2007;15–20.
34.
Cheung A, Szeto E, Leung B, Khoo U, Ng A. Liquid-based cytology and conventional cervical smears: a comparison study in an Asian screening population. Cancer. 2003;331–5.
35.
Fremont-Smith, Marino M, Griffin J, Spencer B, Bolick L, D. Comparison of the SurePath Liquid-based Papanicolaou smear with the conventional Papanicolaou smear in a multisite direct-to-vial study. Cancer. 2004;269–79.
36.
Moscicki A. Impact of HPV infection in adolescent populations. J Adoles Health. 2005;3–9.
37.
Benton E, Arends, Mj. Human papillomavirus in the immunosuppressed. 1996;271–9.
38.
Ostor A. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;(2):186–92.
39.
Tindle R. Human papillomavirus vaccines for cervical cancer. Curr Opin Immunol. 1996;(5):643–50.
40.
Stanimirоvić B, Atanacković J, Babić M, Berisavac M, Bošković V, Vujkov T, et al. 2006;
41.
Hakama M. Cervical Screening in Developing Countries. Obst Gynecol Communications. 2000;21–3.
42.
Bošković V. Kolposkopsko-citološka korelacija. U: Stanimirović B (urednik) Dijagnostika i lečenje oboljenja cerviksa, vagine i vulve. Kolposkopski atlas. Elit-Medica. 2006;269–73.
43.
Kesić V. Kolposkopija i bolesti donjeg genitalnog sistema žene. 2000;
44.
Murphy N, Ring M, Killaea A, Uhlmann V, ’donovan O, Mulcahy M, et al. p16INK4A as a marker for cervical dyskariosis: CIN and cGIN in cervical biopsies and Thin PrepTM smears. J Clin Pathol. 2003;53–63.
45.
Terzić B, Perišić Z, Milošević J, Sasić M, Velimirović M, Dzinić M. 2001;
46.
Smith E, Ritchie J, Summersgill K, Klussmann J, Lee J, Wang D. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer. 2004;766–72.
47.
Yoshida T, Fukuda T, Sano T, Kanuma T, Owada N, Nakajima T. Usefulness of Liquid-Based Cytology Specimens for the Imunocytochemical Study of p16 Expression and Human Papillomavirus Testing. Cancer. 2004;100–8.
Citation
Copyright
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Article metrics
Google scholar:
See link
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
